查看完整行情页>>

|

货币单位:美元(USD)

AcelRx Pharmaceuticals, Inc. (acrx)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
Howard B. Rosen Howard B. Rosen is a businessperson who has been at the head of 5 different companies is Member of National Academy of Engineering and on the board of 6 other companies. In his past career he occupied the position of Principal at Integral, Inc., Consultant at McKinsey & Co., Inc., Vice President-Commercial Strategy at Gilead Sciences, Inc., Chairman of Alcobra Ltd., President & Chief Executive Officer at Pearl Therapeutics, Inc., President for ALZA Corp. and Director-Corporate Development at GenPharm International, Inc. Mr. Rosen received an undergraduate degree from Stanford University, a graduate degree from Massachusetts Institute of Technology and an MBA from Stanford Graduate School of Business.
Mark Allen Wan Founder of 5 different companies, notably: Odyssey HealthCare, Inc., Epocrates LLC and Three Arch Partners, Mark Allen Wan is an entrepreneur and occupies the position of Managing Director at Causeway Management LLC (which he founded in 2013) and Managing Director at Three Arch Partners (which he founded in 2009), Managing Member at Three Arch Management IV LLC and Member of Three Arch Management LP (both are subsidiaries of Three Arch Partners). Mr. Wan is also Managing Member at Three Arch Management IV LLC and Member of Three Arch Management LP and on the board of 10 other companies. In the past Mark Allen Wan occupied the position of General Partner of Brentwood Associates, Director at Odyssey HealthCare, Inc. and Independent Director at Epocrates LLC. Mr. Wan received an undergraduate degree from Yale University and an MBA from Stanford Graduate School of Business.
Adrian Adams Mr. Adrian Adams is a Chairman & Chief Executive Officer at Impel NeuroPharma, Inc., a Chairman at Akebia Therapeutics, Inc., a Chief Executive Officer at Aralez Pharmaceuticals Plc and a Chairman at AcelRx Pharmaceuticals, Inc. Mr. Adams was previously employed as a Chief Executive Officer & Director by POZEN, Inc., a President, Chief Executive Officer & Director by Auxilium Pharmaceuticals LLC, a Chairman & Chief Executive Officer by Neurologix, Inc., a President, Chief Executive Officer & Director by Inspire Pharmaceuticals, Inc., an Independent Director by Amylin Pharmaceuticals, Inc., a President & Chief Executive Officer by Sepracor Pharmaceuticals Inc, a President & Chief Executive Officer by KOS Pharmaceuticals, Inc., a President & Chief Executive Officer by Novartis Pharmaceuticals UK Ltd., a Director-Sales & Marketing by ICI Pharmaceuticals, and a President & Chief Executive Officer by Smithkline Beecham Plc. He also served on the board at Aralez Pharmaceuticals, Inc., Neurocrine Biosciences, Inc. and Pharmaceutical Research & Manufacturers of America. He received his undergraduate degree from The University of Manchester and an undergraduate degree from the University of Salford.
Stephen J. Hoffman Founder of Somatogen, Inc., Stephen J. Hoffman is a businessperson who has been at the head of 6 different companies and currently is Managing Director at Skyline Management LLC. He is also on the board of Dicerna Pharmaceuticals, Inc., AcelRx Pharmaceuticals, Inc. (former Chief Executive Officer & Independent Director), Palleon Pharma, Inc. and Palleon Pharmaceuticals, Inc. In his past career Dr. Hoffman was Chairman for Bicycle Therapeutics Plc, Chairman for Anchiano Therapeutics Ltd., Chief Executive Officer & Director at Aerpio Pharmaceuticals, Inc. and Chief Executive Officer & Director at Aerpio Therapeutics, Inc. (a subsidiary of Aerpio Pharmaceuticals, Inc.), Vice President-Science & Technology at Baxter International, Inc. and Vice President-Science & Technology at Somatogen, Inc. (a subsidiary of Baxter International, Inc.), General Partner for TVM Capital GmbH and General Partner for TVM Capital Corp. (a subsidiary of TVM Capital GmbH) and Chairman of Allos Therapeutics, Inc. Stephen J. Hoffman received a doctorate from Northwestern University and a doctorate from The University of Colorado School of Medicine.
Mark G. Edwards Founder of BioScience Advisors, Inc. and Recombinant Capital, Inc., Mark G. Edwards presently occupies the position of Managing Director at BioScience Advisors, Inc. He is also on the board of AcelRx Pharmaceuticals, Inc. and California Institute for Biomedical Research. In the past Mr. Edwards was Managing Director at Recombinant Capital, Inc., Managing Director & Principal at Deloitte Recap LLC and Manager-Business Development at Chiron Corp. Mark G. Edwards received an MBA and an undergraduate degree from Stanford University.
Vincent J. Angotti Presently, Vincent J. Angotti occupies the position of Chief Executive Officer & Director at AcelRx Pharmaceuticals, Inc. In the past Mr. Angotti held the position of Chief Executive Officer of XenoPort, Inc., Executive Director-Field Operations at Novartis Pharmaceuticals Corp. and Senior Vice President-Sales & Marketing for Reliant Pharmaceuticals LLC. Mr. Angotti received an MBA from Columbia University and an undergraduate degree from Cornell University.
Badri N. Dasu Mr. Badri N. Dasu is a Chief Engineering Officer at AcelRx Pharmaceuticals, Inc., a Member at American Association of Medical Instrumentation and a Member at American Institute of Chemical Engineers. Mr. Dasu was previously employed as a Vice President-Medical Device Engineering by Anesiva, Inc., a Vice President-Manufacturing & Device Development by AlgoRx Pharmaceuticals, Inc., a Vice President-Manufacturing & Process Development by Powderject Pharmaceuticals, Inc., a Director-Process Development by Metrika, Inc., and a Director-Process Development by Cygnus, Inc. He received his undergraduate degree from Mangalore University and a graduate degree from The University of Tulsa.
Richard F. Afable Richard F. Afable is a businessperson who has been at the head of 5 different companies. He is on the board of California Hospital Association (former Chairman), AcelRx Pharmaceuticals, Inc., Providence Little Co. of Mary Medical Institute and OnSite Waste Technologies, Inc. In the past Richard F. Afable was Chief Executive Officer for St. Joseph Hoag Health, Chief Executive Officer at Covenant Health Network, President & Chief Executive Officer at Hoag Hospital Foundation, Chief Medical Officer & Executive Vice President at Catholic Health East, President & Chief Executive Officer for Hoag Memorial Hospital Presbyterian, Inc., Professor at Wake Forest University and Professor at Northwestern University. Dr. Afable received a doctorate and an undergraduate degree from Loyola University of Chicago and a graduate degree from the University of Illinois.
Pamela Pierce Palmer Pamela Pierce Palmer founded Omeros Corp. and AcelRx Pharmaceuticals, Inc. Presently, Dr. Palmer is Independent Director & Chief Medical Officer at AcelRx Pharmaceuticals, Inc. Dr. Palmer is also Professor at The University of California, San Francisco. In the past Dr. Palmer occupied the position of Director-Advanced Research & Education at UCSF Pain Management Center and Director at Omeros Corp. Dr. Palmer received a doctorate from Stanford University, a doctorate from Stanford University School of Medicine and an undergraduate degree from the University of Arizona.
Mark A. Evashenk Mark A. Evashenk is Vice President-Clinical Operations at AcelRx Pharmaceuticals, Inc. In his past career he was Director-Clinical Operations at ALZA Corp. He received an undergraduate degree from the University of California, Davis.
Raffi Asadorian Currently, Raffi Asadorian holds the position of Chief Financial & Accounting Officer at AcelRx Pharmaceuticals, Inc. In the past Mr. Asadorian occupied the position of Chief Financial Officer at Amyris, Inc., Chief Financial Officer for Unilabs SA, Chief Financial Officer & Senior Vice President of PLIVA dd and Partner at PricewaterhouseCoopers LLP. Mr. Asadorian received an undergraduate degree from Xavier University and an MBA from Manchester Metropolitan University of.